Cantex Pharmaceuticals (Weston, Fla.) and Headlamp Health (San Francisco) announced a collaboration to apply Headlamp’s Lumos AI platform to the clinical development of azeliragon for depression and fatigue in patients with multiple sclerosis, with Headlamp deploying its patient-stratification technology across Cantex’s existing azeliragon program data. The partnership arrangement adds an AI-driven phenotyping layer to a drug candidate that Cantex has been advancing across multiple indications since licensing worldwide rights from vTv Therapeutics in 2021.
Azeliragon is an orally administered, once-daily capsule and the only blood-brain barrier-penetrant RAGE inhibitor — targeting the receptor for advanced glycation endproducts — currently in clinical development. Originally developed by vTv Therapeutics for Alzheimer’s disease, azeliragon was licensed by Cantex to pursue new therapeutic indications. The compound inhibits RAGE interactions with ligands including HMGB1 and S100 proteins. In the MS context, RAGE is expressed on microglia, astrocytes, endothelial cells, and infiltrating immune cells in the brain, where activation amplifies neuroinflammatory signaling. Cantex is positioning azeliragon’s anti-neuroinflammatory mechanism as distinct from existing pharmacologic options for MS-related depression and fatigue, which include SSRIs and SNRIs that do not address inflammatory pathways. Clinical safety data from prior trials involving more than 2,000 individuals dosed for periods of up to 18 months indicate the compound is well tolerated, according to the company.
The target population is substantial. Cantex cites that approximately 40% of patients with progressive MS have clinically significant depression, while fatigue affects 60% to 80% of MS patients over the course of the disease. Both symptom domains are described by the company as pharmacologically underserved, with current treatment options showing limited efficacy beyond placebo.
The Lumos AI platform and phenotyping approach
Headlamp Health’s Lumos AI platform is described by the company as a neuro-symbolic, multi-agent system built for neuropsychiatric drug development. The platform integrates biological, behavioral, biomarker, and clinical data into a unified analytical layer, drawing on a proprietary dataset of more than 100 million longitudinal multi-modal data points. In the context of the Cantex Headlamp partnership azeliragon program, Headlamp will deploy Lumos AI to analyze the full body of data generated across azeliragon’s development history, with the goal of delineating distinct responder and non-responder patient phenotypes.